Publications
497 publications
- Date
- Relevance
-
Package advice for the lock procedure medicinal product zanubrutinib (Brukinsa®) for the treatment of chronic lymphocytic leukaemia (CLL)
The National Health Care Institute has assessed whether the CGRP inhibitor eptinezumab (Vyepti®) can be reimbursed from the basic ...
-
GVS advice fenfluramine (Fintepla®) for the treatment of epileptic seizures in Dravet Syndrome or Lennox-Gastaut Syndrome
The National Health Care Institute has assessed whether fenfluramine (Fintepla®) can be included in the Medicine Reimbursement ...
-
GVS advice midazolam (Midazolam Xiromed®) for the treatment of epilepsy
The National Health Care Institute has assessed whether oromucosal administration of midazolam (Midazolam Xiromed®) can be ...
-
GVS advice for tirzepatide (Mounjaro®) for the treatment of adults with type 2 diabetes mellitus without a very high risk of cardiovascular disease
The National Health Care Institute has assessed whether tirzepatide (Mounjaro®) can be included in the Medicine Reimbursement ...
-
Advice - Extension of conditional inclusion procedure for ataluren (Translarna®)
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to extend the conditional ...
-
GVS advice glucagon (Ogluo®) for the treatment of severe hypoglycaemia in adults and children aged 2 years and older
The National Health Care Institute assessed whether the administration of subcutaneous glucagon (administration under the skin) ...
-
Package advice for lock procedure medicinal product darolutamide (Nubeqa®) for the treatment of metastatic prostate cancer
The National Health Care Institute has assessed whether the medicinal product darolutamide in combination with docetaxel and ...
-
Package advice eptinezumab (Vyepti®) for the treatment of migraine
The National Health Care Institute has assessed whether the CGRP inhibitor eptinezumab (Vyepti®) can be reimbursed from the basic ...
-
Package advice for entrectinib and larotrectinib (Rozlytrek® and Vitrakvi®) for the treatment of adult and paediatric patients with solid tumours (cancer) with NTRK gene fusion
The National Health Care Institute has assessed whether the medicinal products entrectinib and larotrectinib (Rozlytrek® and ...
-
GVS advice potassium citrate and potassium hydrogen carbonate (Sibnayal®) for the treatment of distal renal tubular acidosis (dRTA)
The National Health Care Institute has assessed whether the combination preparation potassium citrate and potassium hydrogen ...